First Tracks Posts Q2 Loss, FDA Fast Track for ANB033, Data Readouts Set Through 2027
TRAX has more than doubled off its 52-week low of $14.72.
Summary
First Tracks reported Q2 2026 results with a net loss of $33.4M and cash of $168.0M, providing runway into 2027. The FDA granted Fast Track designation to ANB033 for celiac disease, a regulatory milestone that could accelerate development. Clinical timelines are now concrete: Cohort 1 celiac data in Q4 2026, Cohort 2 in Q1 2027, and eosinophilic esophagitis data in Q3 2027. The company also plans to start Phase 2 trials in two additional indications in H1 2027, broadening the pipeline. This follows the spin-off from AnaptysBio completed in April 2026 and a $180M capital raise, positioning the company for multiple near-term catalysts.
At the time of this announcement, TRAX was trading at $45.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $14.72 to $49.91. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.